Group 1 - The core viewpoint of the article highlights the significant stock price increase of Haixi Pharmaceutical, which rose over 7% and is currently trading at 140.9 HKD, with a market capitalization exceeding 11 billion HKD [1] - Haixi Pharmaceutical is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities, with a pipeline of innovative drugs under development [1] - As of the date of the prospectus disclosure, Haixi Pharmaceutical has approved 15 generic drug products, covering multiple therapeutic areas including the digestive system, cardiovascular system, endocrine system, and nervous system [1] Group 2 - The company has established a pipeline of four innovative drugs currently under development, targeting diseases in oncology, ophthalmology, and respiratory systems [1] - The current average daily market capitalization of Haixi Pharmaceutical has reached 9.94 billion HKD, which is above the threshold required for Hong Kong Stock Connect [1]
港股异动 | 海西新药(02637)一度涨超7% 总市值现突破110亿港元